化疗结合早期加速超分割放疗治疗局限期小细胞肺癌的疗效  

The efficacy of accelerated hyperfractionated radiotherapy combined chemotherapy in limited-stage small cell lung cancer.

作　　者：张中民[1] 吕慧清[1] 

机构地区：[1]临沂市人民医院放疗中心,山东临沂276003

出　　处：《现代肿瘤医学》2006年第4期409-411,共3页Journal of Modern Oncology

摘　　要：目的观察化疗与早期同步加速超分割放疗治疗局限期小细胞肺癌的近期疗效和毒副反应，比较EC方案和EP方案之间的差别。方法40例符合条件的局限期小细胞肺癌行EC方案（E：依托泊甙100mg，第1～5d；C：卡铂400～500mg第1d）或EP方案（E：依托泊甙100mg，第1～5d；P：顺铂40mg第1～3d）化疗6个周期，在化疗早期进行加速超分割放疗45Gy／30次／3周。观察近期疗效和毒副反应，主要是放射性食管炎、放射性肺炎和骨髓抑制情况。结果近期总有效率为95．O％（38／40），EC组有效率95．65％，EP组有效率94．12％，2组间的有效率无明显差别（P=0．871）。放射性食管炎和放射性肺炎以2—3度为主，无4级以上的反应。骨髓抑制在EC方案方案组明显。EC组和EP组的中位生存时间均为24个月。结论化疗结合早期加速超分割放疗治疗局限期小细胞肺癌的近期疗效满意，毒副反应能够耐受，长期效果需进一步观察。Objective To evaluate the therapeutic efect and toxicity of accelerated hyperfractionated radiotherapy combined concurrent chemotherapy for limited - stage small cell lung cancer （ LD - SCLC ）. Methods A total of 40 patients with LD - SCLC initially received six cycles of etoposide and eisplatin （ EC group ） or carboplatin （ EP group ） chemotherapy. All patients pls concerrent thoracic radiotherapy, twice -dally in 1.5Gy/fraction at beginning of cycle 1 or 2 chemotherapy. Results The response rate was 95.0% for all patients, and 96.65% for EC group, 94.12% for EP group, no statistically significant differences were found （ P =0.871 ）. The median survival time was 24 months for two groups. The therapeutic toxicity was grade 2 or 3 radiation espohagitis and pneumonitis, ni more than grade 4 radiation esephagitis or pneumonitis occurred. Conclusion The response was encouraging for accelerated hyperfractiouated radiontherapy combined chemotherapy in LD - SCLC, the therapeutic toxicity could be well tolerated.

关 键 词：小细胞肺癌 加速超分割 同步化疗 

分 类 号：R734.2[医药卫生—肿瘤]